Raymond James & Associates Editas Medicine, Inc. Call Options Transaction History

Raymond James & Associates

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 11, 2022	BUY	$14.08 - $27.63 $28,160 - $55,260	2,000 Added 6.23%	34,100 $89,000
Q2 2021 Aug 11, 2021	BUY	$31.29 - $56.64 $59,451 - $107,616	1,900 Added 6.29%	32,100 $562,000
Q1 2021 May 14, 2021	BUY	$39.71 - $90.58 $1.2 Million - $2.74 Million	30,200 New	30,200 $56,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $86.6M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.